- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
A Discussion on Managing and Treating Type 2 Diabetes
As a progressive condition, diabetes presents an ongoing challenge for physicians to provide adequate control of patients’ disease, and new agents with novel mechanisms of action help reduce the burden in the management of diabetes.
As a progressive condition, diabetes presents an ongoing challenge for physicians to provide adequate control of patients’ disease, and new agents with novel mechanisms of action help reduce the burden in the management of diabetes.
In a recent Peer Exchange discussion, Peter Salgo, MD, of Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, led a discussion on novel agents and their role in treating patients with and without cardiovascular disease. On the panel was Om Ganda, MD, of Joslin Diabetes Center; Jim Kenney of JTKenney, a managed care consulting practice; and Helena Rodbard, MD, FACP, MACE, past president of the American College of Endocrinology and past president of the American Association of Clinical Endocrinologists.
Here, you can listen to part of the discussion.
Listen above or through one of these podcast services:
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
